Login to MyKarger

New to MyKarger? Click here to sign up.



Login with Facebook

Forgot your password?

Authors, Editors, Reviewers

For Manuscript Submission, Check or Review Login please go to Submission Websites List.

Submission Websites List

Institutional Login
(Shibboleth or Open Athens)

For the academic login, please select your country in the dropdown list. You will be redirected to verify your credentials.

Introduction

Molecular Targeted Therapy for Hepatocellular Carcinoma: Bench to Bedside

Kudo M.

Author affiliations

Department of Gastroenterology and Hepatology, Kinki University School of Medicine, Osaka, Japan

Related Articles for ""

Dig Dis 2011;29:273–277

Do you have an account?

Login Information





Contact Information










I have read the Karger Terms and Conditions and agree.



Login Information





Contact Information










I have read the Karger Terms and Conditions and agree.



To view the fulltext, please log in

To view the pdf, please log in

Buy

  • FullText & PDF
  • Unlimited re-access via MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

CHF 38.00 *
EUR 35.00 *
USD 39.00 *

Select

KAB

Buy a Karger Article Bundle (KAB) and profit from a discount!

If you would like to redeem your KAB credit, please log in.


Save over 20% compared to the individual article price.
Learn more

Rent/Cloud

  • Rent for 48h to view
  • Buy Cloud Access for unlimited viewing via different devices
  • Synchronizing in the ReadCube Cloud
  • Printing and saving restrictions apply

Rental: USD 8.50
Cloud: USD 20.00


Select

Subscribe

  • Access to all articles of the subscribed year(s) guaranteed for 5 years
  • Unlimited re-access via Subscriber Login or MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

Subcription rates


Select

* The final prices may differ from the prices shown due to specifics of VAT rules.

Article / Publication Details

First-Page Preview
Abstract of Introduction

Published online: August 09, 2011
Issue release date: August 2011

Number of Print Pages: 5
Number of Figures: 0
Number of Tables: 0

ISSN: 0257-2753 (Print)
eISSN: 1421-9875 (Online)

For additional information: https://www.karger.com/DDI

Abstract

According to the International Agency for Research on Cancer, approximately 670,000 new cases of hepatocellular carcinoma (HCC) developed in 2005, making it the fifth most common cancer and third most common cause of cancer-related death worldwide. HCC is a complex and heterogeneous tumor with several genomic alterations. There is evidence of aberrant activation of several signaling cascades such as EGFR, Ras/Raf/MEK, PI3K/mTOR, HGF/MET, Wnt, Hedgehog and apoptotic signaling pathway. Recently a multikinase inhibitor, sorafenib, has shown survival benefits in patients with advanced HCC. It has been proposed that signaling pathway disruption in cancer can be grouped in six function capabilities, some of which need to be altered for cancer development: self-sufficiency in growth signals, insensitivity to anti-growth signals, evading apoptosis, limitless replicative potential, sustained angiogenesis and tumor invasion and metastases. The aim is to integrate these concepts into the molecular pathogenesis of HCC. It has also been proposed that there are common disturbances universal to all liver cancers on top of the more specific mechanisms. Based on this basic research, a molecular targeted agent has recently been developed. There have been no effective chemotherapeutic agents for advanced HCC. Sorafenib, an oral multikinase inhibitor, has set a milestone in the management of HCC in that it is the first agent to significantly improve the overall survival in patients with advanced HCC in a double-blind, placebo-controlled, phase III study. Clinical trials testing new agents for first- and second-line agents, as well as in combination with existing treatment options such as transarterial chemoembolization or arterial infusion chemotherapy, are ongoing. The results of these trials are therefore eagerly awaited.

© 2011 S. Karger AG, Basel


References

  1. Kim JH, Yu SJ, Park BL, Cheong HS, Pasaje CFA, Bae JS, Lee HS, Shin HD, Kim YJ: TGFBR3 polymorphisms and its haplotypes associated with chronic hepatitis B virus infection and age of hepatocellular carcinoma occurrence. Dig Dis 2011;29:278–283.
    External Resources
  2. Yamazaki K, Masugi Y, Sakamoto M: Molecular pathogensis of hepatocellular carcinoma: altering transforming growth factor-β signaling in hepatocarcinogenesis. Dig Dis 2011;29:284–288.
    External Resources
  3. Farazi PA, DePinho RA: Hepatocellular carcinoma pathogenesis: from genes to environment. Nat Rev Cancer 2006;6:674–687.
  4. Minguez B, Tovar V, Chiang D, Villanueva A, Llovet JM: Pathogenesis of hepatocellular carcinoma and molecular therapies. Curr Opin Gastroenterol 2009;25:186–194.
  5. Villanueva A, Newell P, Chiang DY, Friedman SL, Llovet JM: Genomics and signaling pathways in hepatocellular carcinoma. Semin Liver Dis 2007;27:55–76.
  6. Laurent-Puig P, Zucman-Rossi J: Genetics of hepatocellular tumors. Oncogene 2006;25:3778–3786.
  7. Llovet JM, Bruix J: Molecular targeted therapies in hepatocellular carcinoma. Hepatology 2008;48:1312–1327.
  8. Murata K, Suzuki H, Okano H, Oyamada T, Yasuda Y, Sakamoto A: Hypoxia-induced des-γ-carboxyprothrombin production in hepatocellular carcinoma. Int J Oncol 2010;36:161–170.
  9. Murata K, Suzuki H, Okano H, Oyamada T, Yasuda Y, Sakamoto A: Cytoskeletal changes during epithelial-to-fibroblastoid conversion as a crucial mechanism of des-γ-carboxyprothrombin production in hepatocellular carcinoma. Int J Oncol 2009;35:1005–1014.
  10. Murata K, Sakamoto A: Impairment of clathrin-mediated endocytosis via cytoskeletal change by epithelial to fibroblastoid conversion in HepG2 cells: a possible mechanism of des-γ-carboxyprothrombin production in hepatocellular carcinoma. Int J Oncol 2008;33:1149–1155.
  11. Ueshima K, Kudo M, Takita M, Nagai T, Tatsumi C, Ueda T, Kitai S, Ishikawa E, Yada N, Inoue T, Hagiwara S, Minami Y, Chung H, Sakurai T: Des-gamma-carboxyprothrombin may be a promising biomarker to determine the therapeutic efficacy of sorafenib for hepatocellular carcinoma. Dig Dis 2011;29: 321–325.
    External Resources
  12. Kondrup J, Muller MJ: Energy and protein requirements of patients with chronic liver disease. J Hepatol 1997;27:239–247.
  13. Moriwaki H, Miwa Y, Tajika M, Kato M, Fukushima H, Shiraki M: Branched-chain amino acids as a protein- and energy-source in liver cirrhosis. Biochem Biophys Res Commun 2004;313:405–409.
  14. Marchesini G, Bianchi G, Merli M, Amodio P, Panella C, Loguercio C, Rossi Fanelli F, Abbiati R: Nutritional supplementation with branched-chain amino acids in advanced cirrhosis: a double-blind, randomized trial. Gastroenterology 2003;124:1792–1801.
  15. Muto Y, Sato S, Watanabe A, Moriwaki H, Suzuki K, Kato A, Kato M, Nakamura T, Higuchi K, Nishiguchi S, et al: Effects of oral branched-chain amino acid granules on event-free survival in patients with liver cirrhosis. Clin Gastroenterol Hepatol 2005;3:705–713.
  16. Kumada H, Okanoue T, Onji M, Moriwaki H, Izumi N, Tanaka E, Chayama K, Sakisaka S, Takehara T, Oketani M, et al: Guidelines for the treatment of chronic hepatitis and cirrhosis due to hepatitis C virus infection for the fiscal year 2008 in Japan. Hepatol Res 2010;40:8–13.
  17. Hayaishi S, Chung H, Kudo M, Ishikawa E, Takita M, Ueda T, Kitai S, Inoue T, Yada N, Hagiwara S, et al: Oral branched-chain amino acid granules reduce the incidence of hepatocellular carcinoma and improve event-free survival in patients with liver cirrhosis. Dig Dis 2011;29:326–332.
    External Resources
  18. Fan ST, Lo CM, Lai EC, Chu KM, Liu CL, Wong J: Perioperative nutritional support in patients undergoing hepatectomy for hepatocellular carcinoma. N Engl J Med 1994;331:1547–1552.
  19. Okabayashi T, Nishimori I, Sugimoto T, Maeda H, Dabanaka K, Onishi S, Kobayashi M, Hanazaki K: Effects of branched-chain amino acids-enriched nutrient support for patients undergoing liver resection for hepatocellular carcinoma. J Gastroenterol Hepatol 2008;23:1869–1873.
    External Resources
  20. Poon RT, Yu WC, Fan ST, Wong J: Long-term oral branched chain amino acids in patients undergoing chemoembolization for hepatocellular carcinoma: a randomized trial. Aliment Pharmacol Ther 2004;19:779–788.
  21. Holecek M: Three targets of branched-chain amino acid supplementation in the treatment of liver disease. Nutrition 2010;26:482–490.
  22. Tomiya T, Omata M, Fujiwara K: Significance of branched chain amino acids as possible stimulators of hepatocyte growth factor. Biochem Biophys Res Commun 2004;313:411–416.
  23. Calder PC: Branched-chain amino acids and immunity. J Nutr 2006;136(suppl):288S–293S.
    External Resources
  24. Kakazu E, Ueno Y, Kondo Y, Fukushima K, Shiina M, Inoue J, Tamai K, Ninomiya M, Shimosegawa T: Branched chain amino acids enhance the maturation and function of myeloid dendritic cells ex vivo in patients with advanced cirrhosis. Hepatology 2009;50:1936–1945.
  25. Bruix J, Sherman M, Llovet JM, Beaugrand M, Lencioni R, Burroughs AK, Christensen E, Pagliaro L, Colombo M, Rodes J: Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona 2000 EASL Conference. European Association for the Study of the Liver. J Hepatol 2001;35:421–430.
  26. Bruix J, Sherman M: Management of hepatocellular carcinoma. Hepatology 2005;42:1208–1236.
  27. Bruix J, Sherman M: Management of hepatocellular carcinoma: an update. Hepatology 2011;53:1020–1022.
  28. Group formed to establish ‘Guidelines for Evidence-Based Clinical Practice for the Treatment of Liver Cancer’: Clinical Practice Guidelines for Hepatocellular Carcinoma (in Japanese). Tokyo, Kanehara, 2005.
  29. Makuuchi M, Kokudo N, Arii S, Igaki H, Ikai I, Kaneko S, Kawasaki S, Kudo M, Matsuyama Y, Ohtomo K, et al: Surveillance algorithm and diagnostic algorithm for hepatocellular carcinoma. Hepatol Res 2010;40 (suppl 1):1–144.
  30. Makuuchi M, Kokudo N: Clinical practice guidelines for hepatocellular carcinoma: the first evidence-based guidelines from Japan. World J Gastroenterol 2006;12:828–829.
  31. Kokudo N, Sasaki Y, Nakayama T, Makuuchi M: Dissemination of evidence-based clinical practice guidelines for hepatocellular carcinoma among Japanese hepatologists, liver surgeons and primary care physicians. Gut 2007;56:1020–1021.
  32. Expert Panel of Japan Society of Hepatology: Clinical Practice Manual for Hepatocellular Carcinoma (in Japanese). Tokyo, Igaku-Shoin, 2007.
  33. Kudo M, Okanoue T; Japan Society of Hepatology: Management of hepatocellular carcinoma in Japan: Consensus-based clinical practice manual proposed by the Japan Society of Hepatology. Oncology 2007;72(suppl 1):2–15.
  34. Japan Society of Hepatology: Consensus-Based Clinical Practice Manual of Hepatocellular Carcinoma, ed 2 (in Japanese). Tokyo, Igaku-Shoin, 2010.
  35. Kudo M, Izumi N, Kokudo N, et al: Management of hepatocellular carcinoma in Japan: Consensus-based clinical practice guidelines proposed by the Japan Soceity of Hepatology (JSH) 2010 updated version. Dig Dis 2011;29:339–364.
    External Resources
  36. Arii S, Sata M, Sakamoto M, Shimada M, Kumada T, Shiina S, Yamashita T, Kokudo N, Tanaka M, Takayama T, et al: Management of Hepatocellular Carcinoma: Report of Consensus Meeting in the 45th Annual Meeting of the Japan Society of Hepatology (2009). Hepatol Res 2010;40:667–685.

Article / Publication Details

First-Page Preview
Abstract of Introduction

Published online: August 09, 2011
Issue release date: August 2011

Number of Print Pages: 5
Number of Figures: 0
Number of Tables: 0

ISSN: 0257-2753 (Print)
eISSN: 1421-9875 (Online)

For additional information: https://www.karger.com/DDI


Copyright / Drug Dosage / Disclaimer

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.